275 related articles for article (PubMed ID: 28398426)
1. Reversible cutaneous side effects of vismodegib treatment.
Kwong B; Danial C; Liu A; Chun KA; Chang AL
Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
[No Abstract] [Full Text] [Related]
2. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
[No Abstract] [Full Text] [Related]
3. Vismodegib (Erivedge) for basal cell carcinoma.
Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
[No Abstract] [Full Text] [Related]
4. Persistent alopecia induced by vismodegib.
Alkeraye S; Maire C; Desmedt E; Templier C; Mortier L
Br J Dermatol; 2015 Jun; 172(6):1671-1672. PubMed ID: 25546344
[No Abstract] [Full Text] [Related]
5. Four-year experience with vismodegib hedgehog inhibitor therapy.
Simone PD; Schwarz JM; Strasswimmer JM
J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
[No Abstract] [Full Text] [Related]
6. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases.
Aasi S; Silkiss R; Tang JY; Wysong A; Liu A; Epstein E; Oro AE; Chang AL
JAMA Dermatol; 2013 Feb; 149(2):242-3. PubMed ID: 23426496
[No Abstract] [Full Text] [Related]
7. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
[No Abstract] [Full Text] [Related]
8. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
10. Report of cutaneous side effects of vismodegib treatment.
Caplash G; Curragh DS; Halliday L; Huilgol SC; Selva D
Clin Exp Ophthalmol; 2020 Jan; 48(1):123-125. PubMed ID: 31569297
[No Abstract] [Full Text] [Related]
11. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Demirci H; Worden F; Nelson CC; Elner VM; Kahana A
Ophthalmic Plast Reconstr Surg; 2015; 31(6):463-6. PubMed ID: 25675162
[TBL] [Abstract][Full Text] [Related]
12. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
Kutiel TS; Vornicova O; Bar-Sela G
J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
[No Abstract] [Full Text] [Related]
13. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.
Soura E; Plaka M; Dessinioti C; Chasapi V; Stefanaki C; Antoniou C; Stratigos A
Pediatr Dermatol; 2018 Nov; 35(6):e334-e336. PubMed ID: 30178564
[TBL] [Abstract][Full Text] [Related]
14. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
15. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
Orouji A; Goerdt S; Utikal J; Leverkus M
Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
[No Abstract] [Full Text] [Related]
16. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients.
Girard E; Lacour A; Abi Rached H; Ramdane N; Templier C; Dziwniel V; Desmedt E; Le Rhun E; Mortier L
J Am Acad Dermatol; 2018 Jun; 78(6):1213-1216.e2. PubMed ID: 29203435
[No Abstract] [Full Text] [Related]
18. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.
Koelblinger P; Dummer R; Laimer M; Hecht S; Bauer JW; Gaggl A; Kugler A
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e7-e8. PubMed ID: 28646606
[No Abstract] [Full Text] [Related]
19. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.
Apalla Z; Spyridis I; Kyrgidis A; Lazaridou E; Kyriakou A; Fotiadou C; Pikou O; Sotiriou E; Vakirlis E; Papageorgiou C; Delli F; Moutsoudis A; Manoli SM; Ioannides D; Lallas A
J Am Acad Dermatol; 2021 Dec; 85(6):1589-1592. PubMed ID: 33253837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
